Filing Flows › Comparisons › LXRX vs PYXS
Lexicon Pharmaceuticals vs Pyxis Oncology: LXRX and PYXS compared
Lexicon Pharmaceuticals is the larger company: $11.2M of revenue in its latest quarter (Q3 2026) against $11.0M for Pyxis Oncology (Q4 2025). Lexicon Pharmaceuticals is more profitable, with an operating margin of -128.8% against -165.7%.
Where the money goes: LXRX and PYXS
Lexicon Pharmaceuticals (LXRX) · Q3 2026
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
Pyxis Oncology (PYXS) · Q4 2025
Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%, net loss $18.1M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Lexicon Pharmaceuticals (LXRX) | Pyxis Oncology (PYXS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2025 |
| Revenue | $11.2M | $11.0M |
| Revenue growth, Y/Y | -21% | — |
| Operating margin | -128.8% | -165.7% |
| Net earnings | −$14.0M | −$18.1M |
| Net margin | -124.5% | -164.0% |
| Operating cash flow | −$8.1M | −$10.4M |
Questions
Which is bigger, Lexicon Pharmaceuticals or Pyxis Oncology?
Lexicon Pharmaceuticals is the larger company: $11.2M of revenue in its latest quarter (Q3 2026) against $11.0M for Pyxis Oncology (Q4 2025).
Is Lexicon Pharmaceuticals or Pyxis Oncology growing faster?
Lexicon Pharmaceuticals is more profitable, with an operating margin of -128.8% against -165.7%.
More: Lexicon Pharmaceuticals earnings · how Lexicon Pharmaceuticals makes money · Pyxis Oncology earnings · how Pyxis Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-K filed Mar 23, 2026). Fiscal quarters can end on different dates. Not investment advice.